Annual report pursuant to Section 13 and 15(d)

Subsequent Events (Details)

v3.23.1
Subsequent Events (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Feb. 10, 2023
USD ($)
item
$ / shares
shares
Jan. 27, 2023
USD ($)
$ / shares
shares
Oct. 11, 2022
USD ($)
$ / shares
shares
Feb. 28, 2023
USD ($)
item
$ / shares
shares
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Mar. 31, 2023
USD ($)
Subsequent Events              
Proceeds from issuance of common stock for at-the-market offering, net | $         $ 6,053 $ 9,085  
Avenue              
Subsequent Events              
Common shares issued (in shares)     3,636,365        
Warrants issued     545,454        
Number of shares called by warrants     1        
Proceeds from issuance of common stock for at-the-market offering, net | $     $ 10,300        
Number of warrants to purchase shares     545,454        
Avenue | Pre funded warrants              
Subsequent Events              
Number of shares called by warrants     1        
Purchase price | $ / shares     $ 0.0001        
Subsequent events | Registered direct offering              
Subsequent Events              
Common shares issued (in shares) 16,642,894            
Purchase price of warrants | $ / shares $ 0.835            
Proceeds from issuance of common stock for at-the-market offering, net | $ $ 13,300            
Shares exercisable (as percent) 3.50%            
Number of new operating subsidiaries | item 20            
Threshold period for corporate development transaction 5 years            
Shares exercisable period 10 years            
Market value of shares equivalent 1            
Subsequent events | Avenue              
Subsequent Events              
Common shares issued (in shares)   1,940,299          
Subsequent events | Avenue | License agreements | AnnJi Pharmaceutical Co              
Subsequent Events              
License fee payable | $             $ 3,000
Subsequent events | Avenue | License agreements | AnnJi Pharmaceutical Co | License fee payable within 60 days              
Subsequent Events              
License fee payable | $             2,000
Subsequent events | Avenue | License agreements | AnnJi Pharmaceutical Co | License fee payable within 180 days              
Subsequent Events              
License fee payable | $             $ 1,000
Subsequent events | Avenue | Private offering              
Subsequent Events              
Proceeds from issuance of common stock for at-the-market offering, net | $   $ 2,800          
Subsequent events | Avenue | Private offering | Private placement warrants              
Subsequent Events              
Warrants issued   1,940,299          
Number of shares called by warrants   1          
Purchase price | $ / shares   $ 1.55          
Purchase price of warrants | $ / shares   0.125          
Business acquisition. shares issued, price per share | $ / shares   1.55          
Subsequent events | Avenue | Private offering | Pre funded warrants              
Subsequent Events              
Purchase price | $ / shares   0.0001          
Purchase price of warrants | $ / shares   $ 1.5499          
Subsequent events | Checkpoint [Member] | Registered direct offering              
Subsequent Events              
Common shares issued (in shares)       1,180,000      
Purchase price of warrants | $ / shares       $ 5.25      
Proceeds from issuance of common stock for at-the-market offering, net | $       $ 6,700      
Subsequent events | Checkpoint [Member] | Registered direct offering | Pre funded warrants              
Subsequent Events              
Warrants issued       248,572      
Number of shares called by warrants       1      
Purchase price of warrants | $ / shares       $ 4.2499      
Subsequent events | Checkpoint [Member] | Registered direct offering | Series A warrants              
Subsequent Events              
Number of warrants to purchase shares       1,428,572      
Subsequent events | Checkpoint [Member] | Registered direct offering | Series B Warrants              
Subsequent Events              
Number of warrants to purchase shares       1,428,572      
Subsequent events | Urica | Preferred offering | Class B Preferred shares              
Subsequent Events              
Common shares issued (in shares)       34,160      
Business acquisition. shares issued, price per share | $ / shares       $ 25.00      
Number of additional closings of shares offering | item       2      
Proceeds from issuance of preferred stock | $       $ 800      
Stock offering, aggregate fees paid | $       $ 100